With 90+ approved monoclonal antibody (mAb) drugs in the US, efficient and accurate screening methods for mAb discovery is key. The hybridoma strategy is frequently employed, however, is a labor-intensive, time-consuming task and produces variable scientific results. To optimize this process, an integrated workflow solution has been developed:
Discover all the materials and methods in this application note to speed up and enhance your hybridoma screening process!